The utility and safety of real-time endoscopic-guided mucosal admittance(MA) measurement in patients with inflammatory bowel disease(IBD).

The utility and safety of real-time endoscopic-guided mucosal admittance(MA) measurement in patients with inflammatory bowel disease(IBD). - The clinical utility of MA in patients with IBD.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024825

Enrollment

Registered

2016-11-14

Start date

2016-11-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease (IBD)

Interventions

Tissue Conductance Meter

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who are diagnosed ulcerative colitis or crohn's disease. 2. Patients who are older than 18 years old. 3. Patients from whom written informed consent is obtained.

Exclusion criteria

Exclusion criteria: 1.Patients who have a history of pacemaker or ICD implantation. 2. Patients who have a history of electrical device implantation to b rain such as deep brain stimulation. 3. Patients who have severe disorder of cardiovascular, liver or renal function, infection, and hematopoietic organ. 4. Patients who are judged as being inappropriate for this study by their medical doctor.

Design outcomes

Primary

Measure	Time frame
The clinical utility of MA in patients with IBD.	—

Countries

Japan

Contacts

Public ContactTomoo Nakagawa

Chiba University Hospital Department of gastroenterology

tom20852@hospital.chiba-u.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026